港股异动|信达生物-B涨逾3%抗癌药商业化表现较好获多家机构唱多
格隆汇7月18日丨信达生物-B(1801.HK)现报25.1港元,涨3.51%,暂成交4298万港元,最新总市值290.4亿港元。信达生物-B的抗癌产品sintilimab商业化表现较好,获多家机构唱多。富瑞认为该药品短期内将推动增长,预计公司2022财年转为盈利,首予“买入”评级,目标价34.7港元,较昨日收盘价有43%的上涨空间。摩通料关键临床数据、监管决定及sintilimab商业化表现等,将属信达生物上行的催化剂。重申“增持”评级,目标价33港元。报告还指其股价自6月28日以来累跌约8%,同期MSCI中国康健护理指数则升4%。认为公司基本面仍强劲,股价走弱提供吸纳机会。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.